Table 1.
Trial schedule
| Assessment | Screening | Baseline Week 0 |
Post-treatment Week 8 |
Follow-up Week 20 |
Follow-up Year 10 |
Follow-up Year 30 |
|---|---|---|---|---|---|---|
| Informed consent | ○ | ○ | ||||
| Demographics | ○ | ○ | ||||
| Stroke type | ○ | ○ | ||||
| History of stroke | ○ | ○ | ○ | ○ | ||
| History of disease | △ | ○ | ○ | ○ | ||
| Concomitant medication | △ | ○ | ○ | ○ | ○ | ○ |
| Blood pressure | △ | ○ | ○ | ○ | △ | △ |
| Blood laboratory test | ○ | ○ | ○ | △ | △ | |
| Body mass index | △ | ○ | ○ | ○ | △ | △ |
| Waist circumference | △ | ○ | ○ | ○ | △ | △ |
| Barthel Index | ○ | ○ | ○ | ○ | ○ | |
| FMA Motor Scale | ○ | ○ | ○ | △ | △ | |
| WHOQOL-BREF | ○ | ○ | ○ | ○ | ○ | |
| Adverse events | ○ | ○ | ||||
| Mortality | ○ | ○ | ||||
| Recurrence of stroke | ○ | ○ | ||||
| Treatment method | ○ | ○ |
○, required; △, optional; FMA, Fugl-Meyer Assessment; WHOQOL-BREF, World Health Organization Quality of Life BREF.